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Aim: Studies suggest that hyperoxemia increases short-term mortality after cardiopulmonary 
resuscitation (CPR), but the effect of hyperoxemia on long-term outcomes is unclear. We determined the 
prevalence of early hyperoxemia after CPR and its association with long-term neurological outcome and 
mortality.  
 
Methods: We analysed data from adult cardiac arrest patients treated after CPR in tertiary ICUs during 
2005–2013. We retrieved data from the resuscitation and the first arterial blood sample collected after 
return of spontaneous circulation (ROSC) (severe hyperoxemia defined as PaO2>40kPa and moderate as 
PaO2 16–40kPa). We inspected two outcomes, neurological performance at one year after resuscitation 
according to the Cerebral Performance Category and one-year mortality. We used logistic regression to 
test associations between hyperoxemia and the outcome and interaction analyses to test the effect of 
hyperoxemia exposure on the outcomes in smaller subgroups. 
 
Results: Of 1110 patients 11% had severe hyperoxemia, prevalence was 10% for out-of-hospital arrests, 
13% for in-hospital arrests and 9% for in-ICU arrests. In total 585(53%) patients had an unfavourable 
neurological outcome. Compared to normoxemia, severe (Odds ratio [OR] 0.81, 95% confidence interval 
[CI] 0.50-1.30) and moderate hyperoxemia (OR 0.94 95%CI 0.69-1.27) did not associate with neurological 
outcome. Additionally, hyperoxemia had no association with mortality. In subgroup analyses there were 
no significant associations between severe hyperoxemia and outcomes regardless of cardiac arrest 
location, initial rhythm or time-to-ROSC.  
 
Conclusion: We found no association between early post-arrest hyperoxemia and unfavourable outcome. 
Subgroup analysis found no differential effect depending on arrest location, initial rhythm or time-to-
ROSC. 
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Introduction 
 
Anoxic brain injury is the major cause of disability and death after cardiac arrest (CA), thus any effort 
aiming to alleviate intra-arrest hypoxemia appear intuitively well founded.[1,2]. The latest European 
Resuscitation Council guidelines advocate using 100 % fraction of inspired oxygen (FiO2) during 
cardiopulmonary resuscitation (CPR) and targeting an oxygen saturation level of 94-98% during the post-
resuscitation period.[3] Cerebral blood flow and oxygen supply are compromised during cardiac arrest 
but may change rapidly after the return of spontaneous circulation (ROSC). Experimental evidence 
suggests that extreme hyperoxemia after CA and ROSC may exacerbate reperfusion injury. [1,4,5] 
Harmful effects of hyperoxemia are related to increased oxidative stress which is especially critical for the 
brain and myocardium.[1,6,7] Animal models have suggested that avoiding hyperoxemia after 
resuscitation might reduce the neurological injury.[8,9] Retrospective studies in selected and smaller 
samples showed that hyperoxemia in cardiac arrest may influence short-term outcome.[10,11] The effect 
of hyperoxemia on long-term neurological outcome is less clear. In addition, most of the previous studies 
have focused only on out-of-hospital cardiac arrest (OHCA) patients and studied oxygenation mainly 
during intensive care. Given the differences in the cardiac arrest aetiology, management, and delay to 
treatment the possible harmful effect of hyperoxemia and the severity of the ischaemic insult may vary 
between arrest locations. Inspecting CA occurring in different locations can help to understand if certain 
patient groups are more susceptible to be harmed from severe hyperoxemia exposure than others. The 
design of future interventional trials would benefit from more epidemiological data on the prevalence 
and outcome of hyperoxemia in different settings. If early post-arrest hyperoxemia is found to associated 
with poor neurological outcome, one option would be to limit FiO2 already during CPR.[12] On the other 
hand, some studies have suggested improved outcome with intra-arrest hyperoxemia.[13] Thus, previous 
research is unclear on whether hyperoxemia is harmful when exceeding some threshold or if it is a matter 
of time- and dose-dependent exposure, and further if there is some certain time-point during or after 
resuscitation when exposure is most critical.  
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We aimed to study the impact of early post-ROSC hyperoxemia, as indicated by the first arterial blood gas 
sample obtained within two hours after ROSC, on long-term outcome in a sample of patients treated after 
CA occurring at different locations. We hypothesized that hyperoxemia exposure would be significantly 
associated with poor neurological outcome and higher mortality and that the prevalence of hyperoxemia 
would vary according to CA-location. In addition, we wanted to study if any possible association between 
hyperoxemia and outcome would be different depending on arrest location, initial rhythm or time-to-
ROSC.  
 
Material & methods 
 
Study setting 
We conducted a retrospective cohort study of adult (age ≥18) CA patients treated in the tertiary intensive 
care units (ICUs) of Helsinki University Hospital between 2005–2013. All participating ICUs followed the 
same treatment protocols which did not change significantly during the study period.[14,15] The ethics 
committee of the Operative Division of Helsinki University Hospital (June 2014:194/13/03/02/2014 
TMK02§97) and the Finnish National Institute for Health and Welfare (May 2014:THL/713/5.05.01/2014) 
approved of the study. We included only patients with their first CA event. All patients received CPR 
either prior to the ICU admission or during the ICU stay depending on the arrest location. We included 
OHCA and in-hospital cardiac arrest (IHCA) patients in this study, and we used a separate category for 
cardiac arrests located in the intensive care unit (ICUCA) in which ROSC was achieved. We excluded 
patients lacking information about the neurological outcome and an applicable arterial blood gas sample 
(Figure 1).  
 
Data sources and study variables  
We used the Finnish Intensive Care Consortium (FICC) database to retrospectively identify all adult CA 
patients treated in the ICUs of Helsinki University Hospital 2005–2013. FICC is coordinating a national 
intensive care benchmarking programme.[16] We collected data on hospital survival, APACHE II (Acute 
Physiology and Chronic Health Evaluation II) and SAPS II (Simplified Acute Physiology Score II) 
components and scores from the FICC database.[17,18] We collected information regarding time-to-
ROSC, initial cardiac rhythm, cardiac arrest location, and neurological outcome for survivors one year 
after the arrest from the hospital electronic health records and the date of deaths from Finnish 
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Population Register Centre database. Our data collection and combination of databases are in accordance 
with our previous study.[19]  
 
The primary outcome measure was neurological outcome according to the Pittsburgh Cerebral 
Performance Category (CPC), (CPC 1–2 considered as favourable and CPC 3–5 as unfavourable 
outcome).[20] We evaluated neurological status based on the electronic health records closest to one 
year after CA. As a secondary outcome we inspected overall mortality at 365 days after CA. Our primary 
exposure of interest was arterial PaO2 early on post-resuscitation period. We determined PaO2 from the 
first available arterial blood gas (ABG) sample collected up to two hours after ROSC. We used samples 
collected in hospital and in the pre-hospital setting before hospital admission. We defined severe 
hyperoxemia as PaO2>40kPa, moderate hyperoxemia as PaO2 16–40kPa, normoxemia as PaO2 8–16kPa 
and hypoxemia as PaO2<8kPa, the definition follows thresholds used in previous studies.[21–24]  
 
Statistical analyses 
We compared categorical data using a two-sided chi-squared test. We analysed continuous data using 
non-parametric Mann-Whitney U test (data presented as medians with interquartile ranges [IQR]). We 
considered p-values <0.05 as statistically significant. All continuous variables tested were skewed. We 
used significant variables from the univariate analyses (Table 1) to select variables for the multivariable 
models and tested the variables to avoid multicollinearity. A description of the covariate selection for the 
multivariable model is found in the electronic supplemental material. Before conducting the multivariable 
analysis we applied multiple imputation to estimate missing covariate values in the dataset. In process of 
multiple imputation statistical analysis software made five parallel datasets with missing values estimated 
based on the original values’ minimum, maximum and value distribution. There were missing variables 
with following parameters: initial rhythm, time-to-ROSC, APACHE II score, haemoglobin, creatinine, 
lactate, mean arterial pressure, and glucose. The amount of missing data with each variable was low (< 
5%). Baseline characteristics of complete cases and cases with missing values is presented in electronic 
supplemental material (ESMTable 1). Analyses with the imputed data produces results from the original 
and parallel datasets and finally pooled results combining all the previous.  
 
We conducted multivariable analyses by using logistic regression. Values are presented as odds ratios 
(OR) with 95% confidence intervals (CI). Only pooled values are reported and values from the not imputed 
original data are presented in the supplemental tables. Additionally, we used logistic regression in 
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subanalyses to test interactions between covariates and their effect on outcome. All statistical analyses 
were performed with SPSS statistics 25.0 for mac OS (Armonk, NY: IBM Corp). 
 
Results 
 
We identified 1339 patients who were treated after cardiac arrest in the ICU between years 2005–2013. 
Fifty-four patients who did not achieve ROSC, 94 who lacked information about neurological outcome and 
81 with missed relevant blood gas data were excluded (Figure 1). The remaining 1,110 cases formed the 
study population. Before imputation there were 941 complete cases without missing data. Unadjusted 
analyses were conducted before imputation. Results and the number of missing cases are presented in 
Tables 1 and 2 showing patient characteristics by neurological outcome and unadjusted comparison 
between the outcome and different predictors. 
 
Hyperoxemia prevalence & effect on neurological outcome 
Of the 1,110 patients in the study sample 11% had severe hyperoxemia and 37% had moderate 
hyperoxemia. According to the first ABG sample 9% of patients were hypoxemic. The overall hyperoxemia 
prevalence and prevalence by CA-location is presented in Table 3. Prevalence of severe hyperoxemia 
varied between different arrest locations being 10% for OHCA, 13% for IHCA and 9% for ICUCA patients. 
Hypoxemia was most common in ICUCA (15%) and least common in OHCA (7%). There was a statistically 
significant difference in the occurrence of hyperoxemia between CA-locations (p=0.024).  
 
In the study population 585(53%) had a poor neurological outcome (CPC scores 3–5). Factors related to 
neurological outcome are presented in detail in Table 2. In all oxygen-groups the proportion of poor 
outcomes was similar (52–54%) with no statistically significant differences. In unadjusted regression 
analyses and after adjusting for confounding factors there were no associations between neurological 
outcome and oxygen groups. In unadjusted analyses comparing to the normoxemia the ORs for poor 
neurological outcome in severe hyperoxemia was 1.05 (95% CI 0.71-1.57) and 1.07 (95% CI 0.82-1.39) in 
moderate hyperoxemia. Additionally, in adjusted analyses the difference between oxygen groups was not 
significant, ORs in patients with severe hyperoxemia was 0.89 (95% CI 0.56-1.42) and with moderate 
hyperoxemia 1.07 (95% 0.80-1.45). The adjusted analysis with pooled and original results is presented in 
Table 4. Additionally, we conducted a sensitivity analysis excluding cases with CPC score 5 from the 
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analysis. In this subpopulation severe hyperoxemia was not an independent predictor of poor 
neurological outcome (CPC scores 3–4), (OR 1.61 [95 % CI 0.51–5.12]), see results ESM Table 2. 
 
Mortality 
As a secondary outcome we analysed mortality one year after CA. One-year survival after CA between 
oxygen groups is presented on Kaplan-Meier analysis in Figure 2, no significant differences were detected 
between groups. We also compared survival between oxygen groups in different arrest locations, Kaplan-
Meier analyses are presented in supplemental material in ESM Figure 1, no significant differences in 
survival were found between CA locations. Severe (0.76 95% CI 0.45-1.24) or moderate hyperoxemia 
(0.94 95% CI 0.69-1.27) was not associated with higher one-year mortality compared with normoxemia. 
Results for mortality are presented in supplemental material ESM Table 3.  
 
Effect of hyperoxemia exposure on outcome in different subgroups 
We tested interactions between oxygen level and different covariates to see if oxygen would be a 
significant predictor of the neurological outcome or mortality in different subgroups. We tested the 
following interactions; initial rhythm*PaO2, CA-location*PaO2, and time-to-ROSC*PaO2. PaO2 was tested 
separately as continuous variable and categorical variable. No interactions associated with neurological 
outcome were found. With mortality significant interactions were found between PaO2 and PEA as an 
initial rhythm. Additionally, significant interaction was found between severe hyperoxemia and time-to-
ROSC. The significance level of different interactions is found from ESM Table 4 in supplemental material.  
 
Multivariable model accuracy 
The area under the receiving operating characteristic (ROC) curve was 0.73 for model predicting 
neurological outcome and 0.75 for model predicting one-year mortality. Hosmer Lemeshow test indicated 
fit models (p-value > 0.05).   
 
Discussion 
 
In this retrospective large single-centre study with CA-patients treated in ICU we found no association 
between early exposure to hyperoxemia and long-term neurologic outcome or mortality. These findings 
suggest the lack of clear association between short-term initial hyperoxemia and long-term outcome after 
CA and successful resuscitation. Short-term exposure to hyperoxemia may be common and difficult to 
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avoid given the recommend use of 100% oxygen during CPR. As the injury mechanisms may differ both 
based on severity of the ischemic insults as well as the cause of the arrest we conducted a set of 
interaction analyses and found no clear subgroup differences between early hyperoxemia and 
neurological outcome.  
 
Hyperoxemia prevalence 
Many previous studies define extreme hyperoxemia as 300 mmHg (≈40 kPa) or higher. These studies have 
used varying settings and the overall prevalence for hyperoxemia have varied between 6-
41%.[13,21,23,25–28] We used the same threshold for hyperoxemia as these previous studies and found 
that the prevalence for severe hyperoxemia measured from the first available arterial sample within two 
hours after ROSC was 11%. However, almost 40% were exposed to a moderate level of hyperoxemia 
(PaO2>16 kPa/120 mmHg) according to the first available sample. Previously the highest values for 
hyperoxemia prevalence have been detected when including samples collected prior to hospital 
admission, suggesting the oxygen titration is easier in the hospital.[13,25] Two studies conducted in the 
United States observed a severe hyperoxemia prevalence of 18% and 24% during the ICU stay after 
CA.[21,28] In a general ICU population a prevalence of 11% for hyperoxemia and 29% for moderate 
hyperoxemia has been observed.[26] Slightly higher oxygen values have been detected in studies 
conducted in the United States compared to European studies which may be related to the subtle 
differences in resuscitation guidelines between continents.[3,10,21,26–29] European resuscitation 
guidelines emphasize targeting a peripheral oxygen saturation of 94-98% after ROSC, while the American 
Heart Association guidelines emphasize the avoidance of hypoxemia.[3,29] Our study revealed slight 
differences between hyperoxemia prevalence in different arrest locations, with the highest prevalence 
occurring in IHCA patients. Two other studies reported the prevalence by CA location and their results 
differ from ours. In a study conducted by Bellomo and colleagues the prevalence was slightly higher with 
OHCA and in another study conducted by Nelskylä and colleagues OHCA patients were notably more 
often hyperoxemic compared to IHCA or ICUCA patients (65% vs. 21% and 30%). [23,25]  
Effect of hyperoxemia on outcomes 
The major factor in tissue damage and organ dysfunction after ischemia-reperfusion is the formation of 
reactive oxygen species, the amount of which increases with increasing PaO2.[1,4,5,30] The severity of 
cerebral reperfusion injury is not only defined by arterial PaO2, as cerebral circulatory autoregulation is 
affected by many mediators, making the understanding of CNS reperfusion pathophysiology 
challenging.[31] Furthermore, the optimal level of oxygenation during resuscitation is not known. There is 
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evidence suggesting ROSC is more likely achieved with higher intra-arrest arterial PaO2. [13,32] One 
animal study suggested early hyperoxemia exposure after ROSC is harmful for neuronal tissue but later 
exposure is not.[9] The arterial PaO2 measured soon after ROSC is, after intra-arrest PaO2, the second 
best indicator of oxygenation achieved during resuscitation. As our results indicate no clear association of 
early hyperoxemia, it seems that hyperoxemia exposure during resuscitation and early after ROSC may 
not compromise outcome and would thus not be necessary to avoid. Nonetheless, it may be necessary to 
decrease FiO2 soon after ROSC when arterial oxygenation can be monitored appropriately in order to 
avoid harmful effects of later and prolonged hyperoxemia exposure. 
 
Randomised data on oxygen use after CA are limited. A randomized human pilot study conducted by 
Kuisma and colleagues studied effect of 100% and 30% FiO2 for one hour immediately after ROSC and 
found no differencies in oxygenation or levels of neurone spesific enolase (NSE), a marker of brain 
injury.[33] Jakkula and colleagues, compared the effect of targeting normoxemia (10–15 kPa) or 
moderate hyperoxemia (20–25 kPa) during the first 36 hours of intensive care and no differences in NSE 
levels over time, additionally there was no difference in neurological outcome.[34] Cerebral oxygen 
saturation was significantly higher in the moderate hyperoxemia group but the clinical implication of this 
is unclear. All randomised studies have focused on OHCA-patients. One may assume that the 
pathophysiological processes and the severity of hypoxic brain injury and cardiac failure vary slightly 
depending on the arrest location.[35] In our study early hyperoxemia exposure was not associated with 
neurological outcome or mortality and in sensitivity analyses the association did not change by CA-
location. Further on, we found no difference in the association between hyperoxemia and outcome 
indexed by several factors influencing the severity of hypoxic-ischaemic brain injury i.e. initial rhythm and 
duration of the arrest.  
 
Strengths and limitations 
Our study presents a large sample of patients with detailed data on factors at CA, ICU care and long-term 
outcomes. A difference from previous studies is that we used the first available ABG samples, including 
pre-hospital samples, after ROSC to determine hyperoxemia exposure rather than samples collected not 
until in ICU. Additionally, our data consists of patients with CA occurring in different locations. The 
possible differences between the cardiac arrest aetiology and delay to treatment were recognized from 
the beginning and managed in the statistical analysis design. We performed retrospective sensitivity 
analysis to detect the minimum detectable difference in outcomes between hyperoxemia and non-
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hyperoxemia groups with our sample size. With 95% likelihood we can detect an effect greater than 
0.10/10% in outcomes between the groups. Other studies have shown effects at least 0.12/12%, 
therefore a Type II error seems unlikely.[10,21] 
 
However our study has some limitations. The retrospective method can only point out association and 
not causality. In our dataset ABG samples are not time-stamped, making it uncertain exactly how long 
after ROSC they were collected. However, we excluded samples collected more than two hours after 
ROSC. As we only used one ABG sample to determine PaO2, and are thus unable to determine duration of 
hyperoxemia, it is likely that the exposure in some cases may have been more of an early pulse than 
prolonged exposure. The majority of our cases were OHCAs but for those cases we lack the information 
whether the inspected ABG sample was collected before or after hospital admission. Thus, it is possible 
that oxygen therapy had already been titrated reducing the prevalence of hyperoxemia. In addition, we 
studied long-term outcome, which may be influenced by many other factors as well during the follow up 
period. Lastly, due to missing data, we could not use all included patients in all analyses. However, 
additional analyses with imputed data showed comparable results.  
 
Conclusions 
 
In this study we found no association between early post-ROSC hyperoxemia and outcomes after cardiac 
arrest and successful CPR. Extreme hyperoxemia was fairly uncommon in our study sample including the 
first available arterial blood gas measurement within 2 hours after ROSC. Further, we were unable to 
detect neither harm nor benefit from early hyperoxemia regardless of arrest location, initial rhythm or 
delay to ROSC, suggesting that there is no association between hyperoxemia during and soon after CPR 
and long-term outcome.  
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Figure 1 Flowchart of patient inclusion and exclusion, (FICC = Finnish Intensive Care Consortium  
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 Figure 2 Kaplan Meier analysis of one-year survival between oxygen groups. Groups are defined as 
following: hypoxemia PaO2<8 kPa, normoxemia PaO2 8–16 kPa, moderate hyperoxemia PaO2 16–40 kPa 
and severe hyperoxemia PaO2>40 kPa 
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Table 1 Unadjusted association between neurological outcome and independent predictors, odds are 
presented as a probability of poor outcome (CPC 3–5) 
Predictor (reference cat.) 
OR for poor outcome  
(95% CI) 
p-value Missing 
cases 
PaO2 (normoxemia) 
   Hypoxemia (< 8 kPa) 1.04 (0.68-1.60) 0.85 
 Mod. hyperoxemia (16-40 kPa) 1.07 (0.82-1.39) 0.64 
 Severe hyperoxemia (> 40 kPa) 1.05 (0.71-1.57) 0.80 
 PaCO2 (normocapnia) 
   Hypocapnia (<4,5 kPa) 1.17 (0.83-1.66) 0.37 
 Hypercapnia (> 6 kPa) 1.17 (0.91-1.52) 0.22 
 Age (years) 1.03 (1.02-1.04) <0.001 
 Male gender 1.08 (0.83-1.39) 0.57 
 Time-to-ROSC (min) 1.01 (1.00-1.03) 0.02 93 
Initial rhythm (VT/VF) 
  
50 
PEA 2.94 (2.21-3.91) <0.001 
 Asystole 3.78 (2.54-5.63) <0.001 
 Other 2.53 (0.84-7.62) 0.1 
 CA Location (OHCA) 
   IHCA 1.78 (1.37-2.30) <0.001 
 ICUCA 2.24 (1.47-3.41) <0.001 
 Comorbidities (yes) 
   Chronic renal disease 1.24 (0.67-2.31) 0.5 192 
Lung disease 1.44 (0.90-2.29) 0.13 152 
Liver disease 3.30 (0.99-9.28) 0.05 
 NYHA-class prior CA (NYHA I) 
  
100 
NYHA II 0.96 (0.68-1.36) 0.82 
 NYHA III 1.32 (0.86-2.12) 0.19 
 NYHA IV 1.02 (0.69-1.51) 0.91 
 Modified APACHE score  
(excluding points for PaO2) 1.12 (1.09-1.13) <0.001 5 
Vital signs 
   Central temperature (C°) 1.17 (1.11-1.23) <0.001 33 
MAP (worst during 24h) (mmHg) 0.97 (0.96-0.98) <0.001 12 
Heart rate (bpm) 1.01 (1.005-1.011) <0.001 4 
Respiratory rate 1.04 (1.03-1.06) <0.001 9 
GCS 0.96 (0.94-0.98) <0.001 14 
Laboratory parameters 
   Arterial pH 0.07 (0.03-0.16) <0.001 4 
Plasma glucose (mmol/l) 1.03 (1.01-1.06) 0.005 50 
Lactate (mmol/l) 1.14 (1.10-1.18) <0.001 42 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Haemoglobin (g/l) 0.99 (0.98-0.99) <0.001 23 
Creatinine (μmol/l) 1.003 (1.001-1.004) <0.001 42 
Witnessed by anyone (yes) 0.55 (0.37-0.83) 0.004 19 
Admission type 
   Emergency 2.97 (1.03-7.06) 0.04 4 
Operative 0.76 (0.49-1.16) 0.2 
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Table 2 Baseline characteristics of study population by CPC-score one year after cardiac arrest 
Patient 
characteristics 
All patients in 
group 
Good outcome 
(CPC-scores 1–
2) 
Poor outcome 
(CPC-scores 3–
5)  
p-
value* 
Cases 
missing 
 
no. Of patients (%)/median (IQR) 
  
 
1110 525 (47%) 585 (53%) 
  
PaO2 (kPa) 15.3 (10.5-25.7) 15.2 (10.4-24.6) 15.5 (10.7-26.4) 0.36 
 
PaO2 (No. Of patients 
(%))    
0.97 
 
Hypoxemia (< 8 kPa) 98 (9%) 47 (48%) 51 (52%) 
  
Normoxemia (8-16 kPa) 483 (43%) 232 (48%) 251 (52%) 
  
Moderate hyperoxemia 
(16-40 kPa) 
407 (37%) 189 (46%) 218 (54%) 
  
Severe hyperoxemia (> 
40 kPa) 
122 (11%) 57(47%) 65 (53%) 
  
Gender 
   
0.67 
 
Female 309 (28%) 143 (46%) 166 (54%) 
  
Male 801 (72%) 382 (48%) 419 (52%) 
  
Age (years) 63 (54-71) 60 (50.5-68) 65(56-74) <0.001 
 
ROSC (min) 16 (10-22) 15 (9-21) 18 (10-24) 0.004 93 
PCO2 (kPa) 5.6 (4.8-6.7) 5.6 (4.8-6.5) 5.6 (4.8-6.7) 0.39 
 
PCO2 (No. Of patients 
(%))    
0.53 
 
Hypocapnia (< 4,5 kPa)  212 (19%) 97 (46%) 115 (54%) 
  
Normocapnia (4,5-6 kPa) 473 (43%) 233 (49%) 240 (51%) 
  
Hypercapnia (> 6 kPa) 425 (38%) 195 (46%) 230 (54%) 
  
Initial rhythm 
   
<0.001 50 
VT/VF 643 (61%) 377 (59%) 266 (41%) 
  
PEA 274 (26%) 89 (33%) 185 (68%) 
  
Asystole 132 (12%) 35 (27%) 97 (73%) 
  
Other 11 (1%) 4 (36%) 7 (64%) 
  
CA location 
   
<0.001 
 
OHCA 699 (63%) 370 (53%) 329 (47%) 
  
IHCA 315 (28%) 121 (38%) 194 (62%) 
  
ICUCA 96 (9%) 34 (35%) 62 (65%) 
  
Comorbidity (yes) 
     
Liver disease 18 (2%) 4 (22%) 14 (78%) 0.04 
 
Lung disease 71 (7%) 30 (42%) 41 (58%) 0.45 152 
Renal disease 37 (4%) 16 (43%) 21 (57%) 0.59 192 
NYHA-classification 
(prior CA)    
0.32 100 
I 680 (67%) 342 (50%) 338 (50%) 
  
II 141 (14%) 72 /51%) 69 (49%) 
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III 86 (8%) 33 (40%) 50 (60%) 
  
IV 106 (11%) 51 (48%) 55 (52%) 
  
Modified APACHE II 
score (points for PaO2 
excluded) 
23 (17-29) 19 (15-25) 27 (20-31.25) <0.001 5 
Vital signs  
     
Central temperature (C°) 36.6 (34.8-37.7) 36.1 (34.4-37.6) 37 (35.2-37.8) <0.001 33 
MAP worst during 24h 
(mmHg) 
68 (58-131) 102 (61-119) 65 (54-115) <0.001 12 
Heart rate 55 (44-135) 52 (43-69) 61 (45-120) <0.001 4 
Respiratory rate 14 (10-23) 11 (9-18) 17 (10-26) <0.001 9 
GCS (worst during 24h) 15 (3-15) 15 (8-15) 8 (3-15) <0.001 14 
Laboratory parameters 
     
Arterial pH 7.29 (7.22-7.44) 7.31 (7.25-7.46) 7.28 (7.18-7.41) <0.001 4 
Creatinine (μmol/l) 86 (67-121) 79 (64-99) 98 (71-139) <0.001 42 
P-Glucose (mmol/l) 10.6 (8.2-13.9) 9.9 (7.9-13) 11.2 (8.6-14.4) <0.001 50 
P-Lactate (mmol/l) 4.3 (2.1-7.5) 3.3 (1.8-5.9) 5.5 (3.0-8.9) <0.001 42 
Haemoglobin (g/l) 127 (105-141) 130 (115-143) 121 (100-138) <0.001 23 
Admission Type 
     
Operative (yes) 91 (8%) 48 (53%) 43 (47%) 0.28 
 
Emergency (yes) 1087 (98%) 510 (47%) 577 (53%) 0.063 4 
Witnessed by anyone 
(yes) 
977 (90%) 480 (49%) 497 (51%) 0.001 19 
 * p-value conducted with chi-squared test with categorical and with Mann-Whitney U test with continuous variable 
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Table 3 Overall hyperoxemia prevalence and prevalence by cardiac arrest location 
 
Total 
Hypoxemia 
(PaO2<8 
kPa) 
Normoxemia   
(PaO2 8-16 
kPa) 
Moderate 
hyperoxemia   
(PaO2 16-40 
kPa) 
Severe 
hyperoxemia 
(PaO2 >40 
kPa) 
p-
value* 
 
No. Of  (% of 
total patients) 
No. Of patients (%) 
  All 
patients 1110 98 (9%) 483 (43%) 407 (37%) 122 (11%) 
 
    
 
all with oxygen >16 kPa 529 
(48%) 
 CA-
location 
     
0.024 
       OHCA 699 (63%) 47 (7%) 307 (44%) 272 (39%) 73 (10%) 
 
       IHCA 315 (28%) 37 (12%) 132 (42%) 106 (33%) 40 (13%) 
 
       ICUCA 96 (9%) 14 (15%) 44 (46%) 29 (30%) 9 (9%) 
 * p-value calculated using Chi-Square method 
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Table 4 Adjusted analysis of the neurological outcome, odds are presented as a probability of poor 
outcome (CPC 3–5) 
Predictor (ref. 
Category) 
Pooled OR for 
poor outcome 
(95% CI)* 
p-value Original OR for poor 
outcome (95% CI)** 
p-
value 
PaO2-group (normoxemia) 
  
  
Hypoxemia (< 8 kPa) 0.78 (0.48-1.27) 0.31 0.76 (0.45-1.30) 0.32 
Moderate hyperoxemia 
(16-40 kPa) 1.07 (0.80-1.45) 0.64 
1.02 (0.74-1.41) 0.90 
Severe Hyperoxemia (> 40 
kPa) 0.89 (0.56-1.42) 0.62 
0.83 (0.50-1.37) 0.54 
PaCO2-group 
(normocapnia) 
  
  
Hypocapnia (< 4,5 kPa) 0.88 (0.61-1.28) 0.5 0.84 (0.56-1.25) 0.38 
Hypercapnia (> 6 kPa) 0.93 (0.69-1.26) 0.65 0.84 (0.61-1.16) 0.28 
Initial rhythm (VT/VF) 
  
  
PEA 1.86 (1.31-2.64) <0.001 1.73 (1.19-2.52) 0.004 
Asystole 2.40 (1.50-3.85) <0.001 2.38 (1.43-3.95) 0.001 
Other 2.23 (0.51-9.73) 0.28 2.02 (0.55-7.50) 0.29 
CA-location (OHCA) 
  
  
IHCA 0.99 (0.69-1.43) 0.97 0.93 (0.62-1.38) 0.55 
ICUCA 1.40 (0.82-2.39) 0.22 1.15 (0.64-2.14) 0.61 
Modified APACHE II 
score***  1.08 (1.06-1.10) <0.001 
1.08 (1.05-1.10) <0.001 
MAP 1.00 (0.99-1.001) 0.11 1.00 (0.99-1.001) 0.13 
Creatinine (μmol/l) 1.00 (0.998-1.001) 0.08 1.00 (0.997-1.001) 0.22 
Hb (g/l) 1.00 (0.99-1.003) 0.24 1.00 (0.99-1.004) 0.38 
P-lactate (mmol/l) 1.06 (1.02-1.10) 0.006 1.06 (1.02-1.11) 0.005 
P-glucose (mmol/l) 1.01 (0.99-1.04) 0.38 1.01 (0.99-1.04) 0.43 
*pooled odd ratios are conducted with database in which missig values has been estimated with multiple 
imputation 
**original odd ratios are conducted with database in which all cases with missing values excluded 
*** APACHE II score excluding points for oxygenation Hosmer-Lemeshow goodness of fit test for the 
model conducted with original values p = 0.141 AC
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